Esperion Therapeutics, Inc. (ESPR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Esperion Therapeutics, Inc. (ESPR) Healthcare & Pipeline Overview

Esperion Therapeutics, Inc. develops and commercializes treatments for elevated LDL-cholesterol, primarily NEXLETOL and NEXLIZET. These medications address atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. The company collaborates with Daiichi Sankyo Europe GmbH and Serometrix, positioning itself in the specialty pharmaceutical market with a focus on cardiovascular health.

What Is the Investment Thesis for ESPR?

Esperion Therapeutics presents a focused investment opportunity within the cardiovascular pharmaceutical space. With a market capitalization of $661M, the company's potential lies in the continued adoption and market penetration of NEXLETOL and NEXLIZET. Key value drivers include expanding the prescriber base, securing favorable reimbursement coverage, and demonstrating long-term clinical benefits through ongoing trials. Growth catalysts include potential label expansions and positive outcomes from the PCSK9 inhibitor program. The company's gross margin of 54.1% indicates a solid foundation for profitability as sales volume increases. However, investors should be aware of the risks associated with pharmaceutical development and commercialization, including regulatory hurdles, competition from established therapies, and the need for ongoing clinical data to support long-term efficacy and safety.

Based on FMP financials and quantitative analysis

ESPR Key Highlights

Market Cap of $661M reflects investor valuation of Esperion's current and future potential.

• Gross Margin of 54.1% indicates strong pricing power and efficient cost management in manufacturing.
• Profit Margin of -1.8% highlights the company's current investment in R&D and commercialization efforts.
• Beta of 1.17 suggests that Esperion's stock price is slightly more volatile than the overall market.
• No Dividend Yield reflects the company's focus on reinvesting earnings for growth.

Who Are ESPR's Competitors?

ESPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ESPR's Key Strengths?

Novel non-statin LDL-C lowering therapies.

• Strategic partnerships for market expansion.
• Experienced management team.
• Proprietary drug formulations.

What Are ESPR's Weaknesses?

Reliance on a limited number of products.

• Negative profit margin.
• Competition from established therapies.
• Need for ongoing clinical data.

What Could Drive ESPR Stock Higher?

Potential label expansion for NEXLETOL and NEXLIZET.

• Clinical trial results for long-term cardiovascular outcomes.
• Expansion of market access through formulary coverage.
• Progress in the development of the oral PCSK9 inhibitor program.

What Are the Key Risks for ESPR?

Financial-distress signal — its Altman Z-Score of -2.88 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks or delays.
• Competition from established therapies and generics.
• Unfavorable clinical trial results.
• Dependence on successful commercialization of NEXLETOL and NEXLIZET.
• Patent challenges to proprietary drug formulations.

What Are the Growth Opportunities for ESPR?

• Expansion of NEXLETOL and NEXLIZET into New Patient Subsets: Esperion has the opportunity to expand the use of NEXLETOL and NEXLIZET into patient populations beyond those currently indicated, such as patients with diabetes or chronic kidney disease who are at high risk for cardiovascular events. This expansion could significantly increase the addressable market, potentially adding hundreds of thousands of patients over the next 3-5 years.
• Geographic Expansion into New Markets: Esperion can pursue geographic expansion beyond its current markets, particularly in Asia and Latin America, where the prevalence of cardiovascular disease is rapidly increasing. Entering these markets would require strategic partnerships and regulatory approvals, but could provide substantial revenue growth over the next 5-7 years.
• Development of Novel Combination Therapies: Esperion can leverage its expertise in LDL-C lowering to develop novel combination therapies that address multiple cardiovascular risk factors. This could involve combining NEXLETOL or NEXLIZET with other agents, such as those targeting triglycerides or inflammation, to provide a more comprehensive approach to cardiovascular risk reduction. The timeline for development and approval of such therapies would likely be 5-10 years.
• PCSK9 Inhibitor Program Advancement: Esperion's in-licensed oral, small molecule PCSK9 inhibitor program represents a significant growth opportunity. If successful, this program could provide a more convenient and cost-effective alternative to injectable PCSK9 inhibitors, potentially capturing a significant share of the market. Clinical trials and regulatory approvals are expected to take 3-5 years.
• Strategic Partnerships and Acquisitions: Esperion can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. This could involve partnering with other pharmaceutical companies to co-develop or co-market cardiovascular therapies, or acquiring companies with complementary technologies or products. Such deals could accelerate Esperion's growth and diversification over the next 2-3 years.

What Are ESPR's Competitive Advantages?

• Proprietary drug formulations (NEXLETOL and NEXLIZET).
• Patent protection for bempedoic acid and related compounds.
• Established relationships with key opinion leaders in cardiology.
• Strategic partnerships for market access and product development.

What Does ESPR Do?

Esperion Therapeutics, Inc., founded in 2008 and headquartered in Ann Arbor, Michigan, is a pharmaceutical company dedicated to developing and commercializing innovative medicines aimed at treating patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary focus is on addressing atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH), two significant conditions contributing to cardiovascular risk. Esperion's lead product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets. NEXLETOL is designed to lower LDL-C levels by inhibiting ATP citrate lyase (ACL), an enzyme involved in cholesterol synthesis in the liver. NEXLIZET combines bempedoic acid with ezetimibe, offering a dual-mechanism approach to further reduce LDL-C. Esperion has established a license and collaboration agreement with Daiichi Sankyo Europe GmbH, expanding its reach in the European market. Additionally, the company collaborates with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program, potentially adding another therapeutic option to its portfolio. Esperion's strategic focus on LDL-C reduction and its collaborative approach positions it as a key player in the specialty pharmaceutical market, addressing a critical unmet need in cardiovascular disease management.

What Products and Services Does ESPR Offer?

• Develop and commercialize medicines for patients with elevated LDL-C.
• Offer NEXLETOL (bempedoic acid) as a treatment option.
• Provide NEXLIZET (bempedoic acid and ezetimibe) for enhanced LDL-C lowering.
• Target patients with atherosclerotic cardiovascular disease.
• Address heterozygous familial hypercholesterolemia.
• Collaborate with Daiichi Sankyo Europe GmbH for European market access.
• In-license oral, small molecule PCSK9 inhibitor program from Serometrix.

How Does ESPR Make Money?

• Develop and obtain regulatory approval for novel pharmaceutical products.
• Manufacture and market these products to healthcare providers.
• Generate revenue through direct sales and licensing agreements.
• Invest in research and development to expand product pipeline.

What Industry Does ESPR Operate In?

Esperion Therapeutics operates within the specialty pharmaceutical sector, focusing on cardiovascular disease, a leading cause of mortality globally. The market for LDL-C lowering therapies is substantial, driven by the increasing prevalence of ASCVD and HeFH. The competitive landscape includes established players like Amgen and Sanofi with their PCSK9 inhibitors, as well as generic statins. Esperion differentiates itself with oral, non-statin therapies like NEXLETOL and NEXLIZET, targeting patients who cannot tolerate statins or require additional LDL-C lowering. The industry is characterized by stringent regulatory requirements, high R&D costs, and the need for robust clinical data to demonstrate efficacy and safety.

Who Are ESPR's Key Customers?

• Patients with elevated LDL-C levels.
• Cardiologists and other healthcare providers.
• Pharmacies and hospitals.
• Managed care organizations and insurance companies.

Company Profile

Esperion Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ann Arbor, US. The company is led by CEO Sheldon L. Koenig. ESPR has traded publicly since 2013.

Esperion Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.88 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Esperion Therapeutics, Inc. stands at 2.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

ESPR Valuation & Market Position

With a $661M market cap, Esperion Therapeutics, Inc. sits in the small-cap segment of the market.

Wall Street analysts project Esperion Therapeutics, Inc. revenue of about $387.6M for fiscal 2026, with EPS near $-0.04.

ESPR Financials

ESPR Latest News

ESPR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources